Conatus Pharmaceuticals Inc. (CNAT)

[biotechexpert]

Can anyone elaborate on the primary endpoint for ENCORE-PH? I read that it is mean change in HVPG at week 24 between Emricasan and placebo arms but is there a certain target % change? I see that one of the secondary endpoints is a 20% reduction but is there a % goal for primary?

Also, the pilot trial was 4 weeks. Is there any reason to theorize that the drug would not be more effective with an increase in duration?

Thank you.